Allianz SE Acquires Shares of 29,404 Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Allianz SE bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 4th quarter, Holdings Channel reports. The firm bought 29,404 shares of the medical equipment provider’s stock, valued at approximately $3,099,000.

A number of other institutional investors have also modified their holdings of the stock. CKW Financial Group grew its holdings in Zimmer Biomet by 11.7% in the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock valued at $101,000 after purchasing an additional 100 shares during the period. Romano Brothers AND Company grew its stake in shares of Zimmer Biomet by 1.1% during the 4th quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock valued at $1,000,000 after buying an additional 102 shares during the period. Dorsey & Whitney Trust CO LLC increased its holdings in shares of Zimmer Biomet by 2.3% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider’s stock worth $485,000 after buying an additional 102 shares during the last quarter. M&T Bank Corp raised its position in shares of Zimmer Biomet by 0.4% in the 4th quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider’s stock worth $2,834,000 after buying an additional 108 shares during the period. Finally, Dakota Wealth Management boosted its holdings in Zimmer Biomet by 1.3% in the fourth quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider’s stock valued at $1,016,000 after acquiring an additional 122 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 0.1 %

ZBH opened at $112.21 on Friday. The stock has a market capitalization of $22.34 billion, a PE ratio of 25.22, a P/E/G ratio of 1.95 and a beta of 1.04. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $131.61. The firm’s fifty day moving average price is $107.18 and its 200 day moving average price is $107.02.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the business posted $2.20 earnings per share. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.86%. Zimmer Biomet’s dividend payout ratio (DPR) is 21.57%.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ZBH. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Stifel Nicolaus lifted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. JMP Securities reiterated a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 7th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Royal Bank of Canada decreased their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $124.15.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares of the company’s stock, valued at $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.95% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.